| Clinical data | |
|---|---|
| Other names | MSP1014; MSP-1014.OX |
| Routes of administration | Oral12 |
| Drug class | Serotonin receptor agonist; Serotonin 5-HT2A receptor agonist; Serotonergic psychedelic; Hallucinogen |
MSP-1014 is a serotonergic psychedelic which is under development for the treatment of major depressive disorder, other depressive disorders, and anxiety disorders.345612
It is a prodrug of psilocin similarly to psilocybin, and hence acts as a non-selective serotonin receptor agonist, including of the serotonin 5-HT2A receptor.35627 The animal pharmacodynamics and pharmacokinetics of MSP-1014 have been studied,52 demonstrating a shorter plasma half-life compared to psilocybin.
The drug is under development by Mindset Pharma and Otsuka America Pharmaceutical.3456 As of January 2024, it is in phase 2 clinical trials for major depressive disorder and is in the preclinical stage of development for anxiety disorders and other depressive disorders.346 The chemical structure of MSP-1014 does not yet seem to have been disclosed.345 However, Mindset Pharma patented psilocin derivatives and prodrugs in 2022.8
See also
See also
- Substituted tryptamine
- List of investigational hallucinogens and entactogens
- CT-4201, EB-002, and RE-109 (4-GO-DMT)
- Luvesilocin (4-GO-DiPT)
- MSP-2020
References
References
- Mindset Pharma (14 November 2022). "Mindset Pharma Presents Poster at Neuroscience 2022 Highlighting Preclinical Data on MSP-1014, its Psilocybin-like Lead Drug Candidate". GlobeNewswire News Room (Press release). Retrieved 29 October 2024.
- Araujo JA, Higgins GA, de Lannoy IA, Dean I, Atkinson J, Lanthier J, Slassi M. (2022 November 13). 147.05 / JJ5 - The preclinical safety, behavioural and pharmacokinetics properties of MSP-1014, a novel prodrug of psilocin. Neuroscience 2022. https://www.abstractsonline.com/pp8/#!/10619/presentation/70912
- "MSP 1014". AdisInsight. 9 January 2024. Retrieved 29 October 2024.
- "Delving into the Latest Updates on MSP-1014 with Synapse". Synapse. 26 October 2024. Retrieved 29 October 2024.
- Palfreyman MG, Varty GB, Stang E, Boltaev U, Avery K, Nivorozhkin A (December 2025). "Modification of natural tryptamines for the treatment of neuropsychiatric diseases". J Psychopharmacol. 39 (12): 1338–1350. doi:10.1177/02698811251368362. PMID 41045211.
Another prodrug reported to be a psilocybin-like conjugate, MSP-1014, is under clinical development by Otsuka America Pharmaceutical and Mindset Pharma for the treatment of MDD (Arbe, 2023). While the structure of MSP-1014 has not been disclosed, various long- chain fatty acid ester prodrugs of psilocin have been reported (e.g., see psilocin-O-linoleate in Table 2 (Slassi and Araujo, 2023)). In preclinical studies, SC injection of MSP-1014 in rodents produced a higher HTR with reduced effects on locomotor activity and core body temperature, compared to psilocybin at the same dose, suggesting MSP-1014 may be a better-tolerated prodrug than psilocybin (Araujo et al., 2022).
- "Mindset Pharma Receives Approval for Phase II Clinical Trial Evaluating MSP-1014 for the Treatment of Major Depressive Disorder". BioSpace. 22 June 2023. Retrieved 29 October 2024.
MSP-1014 is a novel and patent-protected prodrug of psilocin, the active metabolite of psilocybin. MSP-1014 is anticipated to exert similar efficacy to psilocybin in improving symptoms of depression. Preclinical studies comparing MSP-1014 to psilocybin suggest that the tolerability of MSP-1014 may be superior to psilocybin.
- Dodd S, Norman TR, Eyre HA, Stahl SM, Phillips A, Carvalho AF, et al. (July 2022). "Psilocybin in neuropsychiatry: a review of its pharmacology, safety, and efficacy". CNS Spectrums. 28 (4): 416–426. doi:10.1017/S1092852922000888. PMID 35811423.
- US 2022/0289774, Slassi A, Araujo J, "Psilocin derivatives as serotonergic psychedelic agents for the treatment of cns disorders", issued 7 March 2023, assigned to Mindset Pharma Inc.